Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Mineralys Therapeutics, Inc. Common Stock (MLYS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: MLYS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.25
1 Year Target Price $36.25
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.37% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 909.20M USD | Price to earnings Ratio - | 1Y Target Price 36.25 |
Price to earnings Ratio - | 1Y Target Price 36.25 | ||
Volume (30-day avg) 8 | Beta -0.18 | 52 Weeks Range 8.24 - 18.38 | Updated Date 07/9/2025 |
52 Weeks Range 8.24 - 18.38 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.87% | Return on Equity (TTM) -56.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 566169253 | Price to Sales(TTM) - |
Enterprise Value 566169253 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.41 | Shares Outstanding 65175300 | Shares Floating 43490817 |
Shares Outstanding 65175300 | Shares Floating 43490817 | ||
Percent Insiders 1.46 | Percent Institutions 98.73 |
Upturn AI SWOT
Mineralys Therapeutics, Inc. Common Stock
Company Overview
History and Background
Mineralys Therapeutics is a biopharmaceutical company focused on developing therapies for hypertension and kidney disease. Founded in 2020, it aims to address unmet needs in hypertension management.
Core Business Areas
- Aldosterone Synthase Inhibitor Development: Focuses on developing lorundrostat, an aldosterone synthase inhibitor, for the treatment of hypertension.
Leadership and Structure
The leadership team includes Jon Congleton (CEO). The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Lorundrostat: Lorundrostat is an aldosterone synthase inhibitor in clinical development for hypertension. It aims to lower blood pressure by reducing aldosterone production. Competitors include existing hypertension medications such as ACE inhibitors, ARBs, diuretics, and beta-blockers.
Market Dynamics
Industry Overview
The hypertension market is large and growing, driven by the aging population and increasing prevalence of lifestyle-related risk factors. It is characterized by established treatments and ongoing innovation.
Positioning
Mineralys is positioned as an innovator with a novel approach to hypertension treatment through aldosterone synthase inhibition. It aims to address patients who are not adequately controlled by existing therapies.
Total Addressable Market (TAM)
The global hypertension market is estimated to be worth billions of dollars. Mineralys targets a segment of this market with patients who have uncontrolled hypertension despite existing treatments.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Lorundrostat)
- Experienced management team
- Focus on a large unmet medical need
Weaknesses
- Single asset company
- Clinical trial risk
- Limited commercial infrastructure
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Competition from existing hypertension drugs
- Regulatory hurdles
- Failure to demonstrate efficacy or safety in clinical trials
Competitors and Market Share
Key Competitors
- AZN
- NVS
- PFE
Competitive Landscape
Mineralys faces competition from established pharmaceutical companies with broad portfolios of hypertension medications. Its competitive advantage lies in the potential for lorundrostat to address unmet needs in patients with uncontrolled hypertension.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the advancement of lorundrostat through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of lorundrostat. Analyst estimates may vary significantly based on perceived risk and potential market opportunity.
Recent Initiatives: Recent initiatives include ongoing clinical trials for lorundrostat.
Summary
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing Lorundrostat for hypertension. Its success hinges on positive clinical trial outcomes. The company faces competition from established treatments and requires significant funding. A major success could lead to acquisition by a larger Pharma company or partnership with a big pharma company. It should continue to raise money and be careful not to overspend.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mineralys Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Radnor, PA, United States | ||
IPO Launch date 2023-02-10 | President, CEO & Director Mr. Jon Congleton | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://mineralystx.com |
Full time employees 51 | Website https://mineralystx.com | ||
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.